CRISPR Therapeutics Attempts Breakout on FDA Fast Track

CRISPR Therapeutics Attempts Breakout on FDA Fast Track

CRISPR Therapeutics shares moved sharply higher after the FDA Fast Tracked the company's gene therapy targeting beta thalassemia.